GlassScriptPhysician profile
Elyse Lynn Brack
NPI 1235486036
$6,868.52
in general payments reported to CMS, 2019-2025
25 companies · $1,640 in 2025
The $1,640 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $478 · 2022: $922 · 2023: $1,762 · 2024: $2,068 · 2025: $1,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,451 · Education: $18.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,450.95 |
| Education | $18.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,998.28 | 2021-2025 | |
| Janssen Biotech, INC. | $1,594.58 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $714.17 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $581.77 | 2021-2025 | |
| Ucb, INC. | $427.50 | 2022-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $213.84 | 2024-2025 | Dupixent |
| Galderma Laboratories, L.P. | $175.67 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Leo Pharma INC. | $156.30 | 2021-2023 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $149.02 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $116.72 | 2022-2025 | Jublia, Arazlo, Cabtreo |
| Organon LLC | $109.68 | 2024-2025 | Hadlima, Nexplanon, Vtama |
| Arcutis Biotherapeutics, INC. | $93.39 | 2023-2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.59 | 2023-2024 | Spevigo |
| Amgen INC. | $65.93 | 2023-2024 | Otezla |
| Dermavant Sciences, INC. | $65.51 | 2023-2024 | Vtama |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $65.43 | 2023-2025 | Ilumya, Blu-U |
| Incyte Corporation | $59.19 | 2022-2025 | Opzelura |
| Almirall LLC | $47.06 | 2022-2025 | Klisyri, Seysara |
| Pfizer INC. | $33.68 | 2022-2023 | |
| Sandoz INC. | $33.60 | 2023-2024 | Hyrimoz |
| Genentech USA, INC. | $18.55 | 2024 | Erivedge |
| Verrica Pharmaceuticals INC. | $18.15 | 2025 | Ycanth |
| Convatec INC. | $16.21 | 2024 | |
| Botanix Sb INC | $14.10 | 2025 | Sofdra |
| Kerecis Limited | $12.60 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elyse Brack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.